FindTrial
Sign In

LY2157299

DRUG10 trials

Sponsors

Eli Lilly and Company, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Providence Health & Services

Conditions

Carcinoma, HepatocellularGliomaHealthy VolunteersHepatocellular CarcinomaNeoplasm MetastasisNeoplasmsPancreatic NeoplasmsProstate Cancer

Phase 1

A Study Combining LY2157299 With Temozolomide-based Radiochemotherapy in Patients With Newly Diagnosed Malignant Glioma
CompletedNCT01220271
Eli Lilly and CompanyGlioma
Start: 2011-04-30End: 2016-11-30Updated: 2017-02-16
A Dose-Escalation Study in Participants With Recurrent Malignant Glioma
CompletedNCT01682187
Eli Lilly and CompanyGlioma
Start: 2005-12-15End: 2024-09-30Updated: 2024-11-07
Study of LY2157299 in Japanese Participants With Cancer
CompletedNCT01722825
Eli Lilly and CompanyNeoplasm Metastasis, Neoplasms
Start: 2012-11-30End: 2014-06-30Target: 12Updated: 2014-07-01
A Study of LY2157299 in Healthy Participants
CompletedNCT01965808
Eli Lilly and CompanyHealthy Volunteers
Start: 2013-10-31End: 2013-12-31Target: 16Updated: 2013-12-04
A Study of LY2157299 in Participants With Pancreatic Cancer That is Advanced or Has Spread to Another Part of the Body
CompletedNCT02154646
Eli Lilly and CompanyPancreatic Neoplasms
Start: 2014-05-31End: 2015-07-31Updated: 2016-02-10
A Study of LY2157299 in Participants With Unresectable Hepatocellular Cancer (HCC)
CompletedNCT02240433
Eli Lilly and CompanyHepatocellular Carcinoma
Start: 2014-11-12End: 2019-12-25Updated: 2020-02-05

Phase 2

A Study of LY2157299 in Participants With Hepatocellular Carcinoma
CompletedNCT01246986
Eli Lilly and CompanyCarcinoma, Hepatocellular
Start: 2011-03-30End: 2019-12-24Updated: 2021-01-12
A Study of LY2157299 in Participants With Advanced Hepatocellular Carcinoma
CompletedNCT02178358
Eli Lilly and CompanyHepatocellular Carcinoma
Start: 2014-08-08End: 2021-02-18Updated: 2022-02-25
Study of TGF-β Receptor Inhibitor Galunisertib (LY2157299) and Enzalutamide in Metastatic Castration-resistant Prostate Cancer
Active, not recruitingNCT02452008
Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsProstate Cancer
Start: 2016-05-03End: 2026-12-31Target: 60Updated: 2025-12-19
ExIST Study of LY2157299 (Galunisertib) in Rectal Cancer
Active, not recruitingNCT02688712
Providence Health & ServicesRectal Adenocarcinoma
Start: 2016-03-24End: 2026-12-01Target: 50Updated: 2026-04-13

Related Papers

Can TGF-β inhibition (galunisertib) enhance response to enzalutamide in metastatic castration-resistant prostate cancer (mCRPC)?: Results from a randomized phase II trial.
Journal of Clinical Oncology2026-05-27
CNSC-53. SHARED REGULATION OF QUIESCENCE PATHWAYS BETWEEN NEURAL AND GLIOMA STEM CELLS REVEALS TGF-Β SIGNALLING AS A THERAPEUTIC TARGET IN GLIOBLASTOMA
Neuro-Oncology2025-11-01
A novel structural modeling magnitude and orientation radiomic descriptor for evaluating response to neoadjuvant therapy in rectal cancers via MRI
npj Precision Oncology2025-07-011 citations
New advances in cancer therapy targeting TGF-β signaling pathways
Molecular Therapy — Oncolytics2023-12-0127 citations
Signaling pathways in cancer-associated fibroblasts: recent advances and future perspectives.
2022-11-24186 citations
Galunisertib plus neoadjuvant chemoradiotherapy in patients with locally advanced rectal cancer: a single-arm, phase 2 trial.
2022-08-0897 citations
A phase II trial of TGFβ type I receptor inhibitor, galunisertib, plus neoadjuvant chemoradiation in patients with locally advanced rectal cancer.
Journal of Clinical Oncology2022-06-012 citations
Biomarkers and overall survival in patients with advanced hepatocellular carcinoma treated with TGF-βRI inhibitor galunisertib.
2020-03-2547 citations
Phase 1b/2a study of galunisertib, a small molecule inhibitor of transforming growth factor-beta receptor I, in combination with standard temozolomide-based radiochemotherapy in patients with newly diagnosed malignant glioma.
2020-03-05105 citations
Novel transforming growth factor beta receptor I kinase inhibitor galunisertib (LY2157299) in advanced hepatocellular carcinoma
Liver International2019-04-09134 citations
A phase 2 study of galunisertib (TGF-Β R1 inhibitor) and sorafenib in patients with advanced hepatocellular carcinoma (HCC).
Journal of Clinical Oncology2017-05-206 citations
Abstract 1076: Plasma microRNAs associated with overall survival in patients with hepatocellular carcinoma treated with galunisertib (LY2157299 monohydrate), an inhibitor of transforming growth factor-β receptor1
Cancer Research2016-07-15
A phase 2 study of galunisertib, a novel transforming growth factor-beta (TGF-β) receptor I kinase inhibitor, in patients with advanced hepatocellular carcinoma (HCC) and low serum alpha fetoprotein (AFP).
Journal of Clinical Oncology2016-05-2026 citations
Phase 1 study of galunisertib, a TGF-beta receptor I kinase inhibitor, in Japanese patients with advanced solid tumors.
2015-11-0375 citations